COLORADO SPRINGS, Colo., Dec. 22 /PRNewswire-FirstCall/ -- Spectranetics Corporation today announced the Company's CLiRpath(R) Excimer Laser Catheters were featured in the "Health Headlines" segment on WFXT Fox television evening news in Boston, Mass. at 5:00 p.m. and 10:00 p.m. on December 9, 2004. The segment featured the treatment of peripheral vascular disease with Spectranetics' CLiRpath excimer laser catheter at Brigham and Women's Hospital by Dr. Andrew Eisenhauer, and included favorable testimonial by a patient approximately one month post-procedure.
"Television news health segments such as our recent coverage in Boston are potentially powerful additions to our marketing communication strategy, which is focused on physician training, podiatry outreach, public relations aimed at assisting hospitals in their local markets, and economic outcomes study results," said John G. Schulte, president and chief executive officer of Spectranetics. "I'm delighted with the clinical outcomes by physicians treating peripheral vascular disease with our CLiRpath excimer laser catheters and the progress of the CLiRpath product launch, which is focused on the 120 hospitals with identified potential users that already have an excimer laser system."
Commenting on his experience with CLiRpath excimer laser catheters, Dr. Eisenhauer said, "The addition of the excimer laser to other innovative techniques in our practice allows us to treat peripheral vascular disease and critical limb ischemia more successfully and has improved patient quality of life and procedure success rates."
Dr. Andrew Eisenhauer is Director of the Interventional Cardiovascular Medicine Service at the Brigham and Women's Hospital and Assistant Professor of Medicine at The Harvard Medical School. He and his colleagues have pioneered a systematic approach to the diagnosis and treatment of vascular disease in a variety of patient situations. He can be reached at 617 732-8898.
CLiRpath(R) Excimer Laser Catheters are indicated for use in the endovascular treatment of symptomatic infrainguinal lower extremity vascular disease where total obstructions cannot be crossed with standard guide wires.
About Spectranetics
Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Our CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary and peripheral atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of our FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004, we obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.
For further information please contact: John Schulte, Chief Executive Officer, or Guy Childs, Chief Financial Officer, both of Spectranetics Corporation, +1-719-633-8333; or investors & media, Bruce Voss or Ina McGuinness of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for Spectranetics Corporation.
Spectranetics Corporation
"Television news health segments such as our recent coverage in Boston are potentially powerful additions to our marketing communication strategy, which is focused on physician training, podiatry outreach, public relations aimed at assisting hospitals in their local markets, and economic outcomes study results," said John G. Schulte, president and chief executive officer of Spectranetics. "I'm delighted with the clinical outcomes by physicians treating peripheral vascular disease with our CLiRpath excimer laser catheters and the progress of the CLiRpath product launch, which is focused on the 120 hospitals with identified potential users that already have an excimer laser system."
Commenting on his experience with CLiRpath excimer laser catheters, Dr. Eisenhauer said, "The addition of the excimer laser to other innovative techniques in our practice allows us to treat peripheral vascular disease and critical limb ischemia more successfully and has improved patient quality of life and procedure success rates."
Dr. Andrew Eisenhauer is Director of the Interventional Cardiovascular Medicine Service at the Brigham and Women's Hospital and Assistant Professor of Medicine at The Harvard Medical School. He and his colleagues have pioneered a systematic approach to the diagnosis and treatment of vascular disease in a variety of patient situations. He can be reached at 617 732-8898.
CLiRpath(R) Excimer Laser Catheters are indicated for use in the endovascular treatment of symptomatic infrainguinal lower extremity vascular disease where total obstructions cannot be crossed with standard guide wires.
About Spectranetics
Spectranetics is a medical device company that develops, manufactures and markets single-use medical devices used in minimally invasive surgical procedures within the cardiovascular system in conjunction with its proprietary excimer laser system. Our CVX-300(R) excimer laser is the only system approved by the FDA for multiple cardiovascular procedures, including coronary and peripheral atherectomy, and the removal of problematic pacemaker and defibrillator leads. Nearly all of our FDA-approved and investigational applications have received Communautes Europeennes (CE) mark registration for marketing within Europe. In April 2004, we obtained 510(k) clearance from the FDA for the laser-based treatment of patients suffering from total occlusions (blockages) in their leg arteries that are not crossable with a guide wire.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
Spectranetics and CVX-300 are registered trademarks of The Spectranetics Corporation.
For further information please contact: John Schulte, Chief Executive Officer, or Guy Childs, Chief Financial Officer, both of Spectranetics Corporation, +1-719-633-8333; or investors & media, Bruce Voss or Ina McGuinness of Lippert/Heilshorn & Associates, Inc., +1-310-691-7100, for Spectranetics Corporation.
Spectranetics Corporation
© 2004 PR Newswire
